Predicting warfarin dose.

Area of Science:

• Pharmacogenetics
• Clinical Pharmacology
• Drug Metabolism

Background:

• Genetic polymorphisms in warfarin metabolism and action affect its dosage.
• Dosing algorithms incorporating genetic data may improve upon usual care, but clinical advantage remains uncertain.

Purpose of the Study:

• Review current knowledge on clinical and genetic determinants of warfarin dosing.
• Summarize pharmacogenetics-based predictive models and their performance.
• Evaluate alternative predictive models not using genetic information.

Main Methods:

• Literature review of clinical and genetic warfarin dosing determinants.
• Analysis of pharmacogenetics-based predictive models.
• Assessment of alternative forecasting models using early warfarin response.

Main Results:

• Pharmacogenetics-based models explain only 35-50% of warfarin dose variability.
• Alternative forecasting models using early responses to fixed-dose nomograms show comparable or superior performance.
• These alternative models do not require expensive genetic testing.

Conclusions:

• Current pharmacogenetics-based warfarin dosing models have limitations in predicting dose variability.
• Alternative models using early response data present a promising, cost-effective approach.
• Routine use of pharmacogenetics-based models in clinical practice is not currently recommended; further comparative studies are needed.